CCG 2961: CHILDREN W/ UNTREATED AML IMMUNE MODULATION PHASE W/ IL 2

这项研究方案是儿童癌症组织(CCG)治疗AML的多中心临床试验的最后阶段：CCG-2961。在患者获得缓解并完成大剂量化疗的诱导和强化治疗阶段后，患者被随机分为接受或不接受IL-2治疗。这种治疗需要住院患者持续输注大剂量IL-2×96小时，4天后再连续输注10天门诊患者低剂量IL-2。

This research protocol is the final phase of the Children's Cancer Group (CCG) multicenter clinical trial for treatment of AML: CCG-2961. After patients have obtained remission and completed the Induction and Intensification phases of treatment with high dose chemotherapy, patients are randomized to receive or not receive treatment with IL-2. This treatment requires in-patient continuous infusion of high dose IL-2 x 96 hours, followed 4 days later by 10 days of continuous infusion out-patient low dose IL-2.